Physician profile
Mayer E Ballas
NPI 1215968318
$1,846.64
in general payments reported to CMS, 2019-2025
12 companies · $240 in 2025
The $240 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $573 · 2020: $226 · 2021: $333 · 2022: $125 · 2023: $20.11 · 2024: $329 · 2025: $240.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $589.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $588.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $535.37 | 2021-2025 | Verquvo |
| Amgen INC. | $438.20 | 2019-2025 | Repatha, Repatha |
| Amarin Pharma, INC. | $259.44 | 2019-2021 | |
| Regeneron Healthcare Solutions, INC. | $209.74 | 2019 | |
| Pfizer INC. | $87.49 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $75.28 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $65.87 | 2021-2024 | Livalo |
| Gilead Sciences, INC. | $48.58 | 2019 | |
| Esperion Therapeutics, INC. | $46.25 | 2020-2024 | Nexletol |
| Novartis Pharmaceuticals Corporation | $42.52 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $20.08 | 2022 | |
| Abbott Laboratories | $17.82 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mayer Ballas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.